NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Status:
Recruiting
Trial end date:
2032-12-25
Target enrollment:
Participant gender:
Summary
Primary aim: Pathological complete response rate after preoperative chemotherapy is the
primary end-point of the study, which will be evaluated by comparing the effects of
neoadjuvant administration of a carboplatin-based treatment and treatment adding capecitabine
on Pathological Complete Response (pCR).
Phase:
Phase 3
Details
Lead Sponsor:
Lund University Hospital
Collaborators:
Danish Breast Cancer Cooperative Group Finnish Breast Cancer Group Icelandic Breast Cancer Group Swedish Breast Cancer Group